


Symposium 6 *Neuro Vaccines*

Vaccines to Prevent Brain Damage in Newborns/Fetuses

Hiroyuki Moriuchi, MD, PhD

Department of Pediatrics, Graduate School of Biomedical Sciences School of Tropical Medicine & Global Health Nagasaki University, Japan




Disclosure Information


Hiroyuki Moriuchi

I have the following financial relationships to disclose:

✓ Honoraria (Lecture fee) from: Merck (MSD), GSK

I will mention a number of unapproved vaccines, including ones developed by the abovementioned companies.





- Brain damage (microcephaly, hydrocephalus, calcification, cortical atrophy, etc.)
- Sensorineural hearing loss
- Chorioretinitis

TORCH complex

Toxoplasma


Herpes simplex virus


Cytomegalovirus

Others

(Syphilis, Zika virus)

Rubella





TORCH complex

Toxoplasma


Herpes simplex virus

Cytomegalovirus

Others

(Syphilis, Zika virus)

Rubella



Burden of Congenital CMV Infection

Congenital CMV infection rates in live births

Japan*	0.32%
North America, Europe, & Australia	0.5 – 1%
Latin America, Africa & most Asian countries	1 – 2%

Estimated annual live births with congenital CMV


Brazil	~ 35,000	
India	270,000 ~ 540,000	
Japan*	3,000	
Nigeria	65,000 ~ 130,000	
USA	20,000 ~ 30,000	

https://www.who.int/immunization/research/meetings_workshops/PDVAC_2017_CMV_Plotkin.pdf?ua=1 *Koyano S, Inoue N, Oka A, Moriuchi H, et al. BMJ Open 2011;1:000118



Estimates of the annual burden of the prominent childhood diseases/syndromes in the USA

An estimated 40,000 children are born with congenital CMV, causing an estimated 400 deaths and leaving approximately 8,000 children with permanent disabilities every year.



Number of children with long-term sequelae

Number of childhood deaths

Vaccines for the 21st Century

Institute of Medicine, USA

http://www.nap.edu/catalog/550.html


Candidate vaccines according to a cost-effectiveness ratio of cost per QALY

Level I	Most favorable	Save money and QALYs
Level II	More favorable	Costs <\$10,000 per QALY saved
Level III	Favorable	Costs >\$10,000 and <\$100,000 per QALY
Level IV	Less favorable	Costs >\$100,000 per QALY saved


- CMV vaccine administered to 12-year-olds
- **Group B streptococcus vaccine** to be well-incorporated into routine prenatal care and administered to women during first pregnancy and to high-risk adults
- **Influenza virus vaccine** administered to the general population (once per person every 5 years, or one-fifth of the population
- Insulin-dependent diabetes mellitus therapeutic vaccine
- Multiple sclerosis therapeutic vaccine
- Rheumatoid arthritis therapeutic vaccine
- Streptococcus pneumoniae vaccine to be given to infants and to 65-year-olds



Several decades of extensive research have not met such urgent need



Inducing Cell-mediated Immunity



Copyright 1994 - '97 Marko Reschke

Maternal humoral immunity did not prevent congenital CMV infection

The New England Journal of Medicine 2001; 344: 1366-71

INTRAUTERINE TRANSMISSION OF CYTOMEGALOVIRUS TO INFANTS OF WOMEN WITH PRECONCEPTIONAL IMMUNITY

SURESH B. BOPPANA, M.D., LISA B. RIVERA, M.P.H., M.B.A., KAREN B. FOWLER, DR.P.H., MICHAEL MACH, PH.D., AND WILLIAM J. BRITT, M.D.

Eleven of the 16 mothers with infected infants (69%) had antibodies against the gH epitopes present on two laboratory CMV strains, AD169 and Towne.

In a woman who is seropositive for CMV, reinfection with a different CMV strain can lead to intrauterine transmission and symptomatic congenital infection.



Short communication

Cytomegalovirus (CMV) glycoprotein H-based serological analysis in Japanese healthy pregnant women, and in neonates with congenital CMV infection and their mothers

Kazufumi Ikuta^a, Toshio Minematsu^b, Naoki Inoue^c, Takahiko Kubo^d, Kimisato Asano^e, Kei Ishibashi^f, Takashi Imamura^g, Hidetaka Nakai^h, Tetsushi Yoshikawa^h, Hiroyuki Moriuchiⁱ, Shigeyoshi Fujiwara^j, Shin Koyano^k, Tatsuo Suzutani^{a,*}



Two (11%) of 18 cases of congenital CMV infection occurred via maternal CMV reinfection.

Maternal humoral immunity did not prevent congenital CMV infection with another gH subtype.

Likelihood of Transplacental Transmission of CMV from Mothers with Primary and Non-primary infection

From motherswith primary infection30 ~ 50%with non-primary infection0.2 ~ 2%

Estimated Annual Number of Children with Congenital CMV in the USA from Mothers with Primary and Non-primary Infection during Pregnancy

<u>Children with congenital CMV</u> born to seronegative mothers born to seropositive mothers Wang et al., Clin Infect Dis 2011

3,722 (4,419 ~ 16,049) **29,918** (23,508 ~ 36,830)

Non-primary infection occurs more frequently than primary infection

Challenges for Developing CMV Vaccines

- Protective immune responses have not been defined.
- Preexisting seroimmunity does not provide complete protection.
- Most infants with congenital CMV in highly seropositive populations including low- and middle-income countries (LMIC) are born to mothers with preexisting seroimmunity.

Vaccine strategies that have been focused on preventing primary maternal infection during pregnancy may not be appropriate.

• Precise estimates of disease burden in LMIC are limited.

Insufficient interest by vaccine manufacturers and policymakers.

CMV Vaccine Candidates in Development or Clinical Trials

Live CMV Vaccines

Vaccine		Manufacturer	Clinical trials
Towne-Toledo chimera		MedImmune	
Replication-defective virus		Merck	Phase IIb
Alphavirus replicon		Novartis	Phase I
Vectored	MVA	City of Hope	Phase I
	Adeno	Queenland Inst	
	LCMV	Hookipa	Phase II
	ALVAC	Pasteur/Merieux	

Non-living CMV Vaccines

ine (platform/Ag)	Manufacturer	Clinical trial
	۹D	Sanofi Pasteur	Phase II
	gв	GSK	
iant)	Pentameric gH complex	Human Biomed	
5		City of Hope	
gB +	pp65	Actolloc	Phase III
gB +	pp65 + IE1	Astellas/vical	Phase I
RNA	in LNP)	GSK/Moderna	
odie	S	Vaccine Project Management (Germany)	
gВ		Variation Biotech	Phase I
eVLP* gB, pentameric gH, etc		RedVax GmbH	
	ant) gB + gB + RNA odies gB gB, p	gB + pp65 + IE1 RNA in LNP) odies	$\begin{array}{llllllllllllllllllllllllllllllllllll$

*enveloped virus-like particle

TORCH complex

Toxoplasma


Herpes simplex virus

Cytomegalovirus

Others

(Syphilis, Zika virus)

Rubella



Enveloped ssRNA(+) virus

Yellow fever virus


Dengue virus



West Nile virus


Japanese encephalitis virus


Zika Virus Transmission Cycle




Microcephaly








Scenarios from Introduction through Outbreak to Endemic of Zika Virus Infection



Children are susceptible

Children are almost exclusively infected with the virus

Mapping global environmental suitability for Zika virus Messina JP et al. e-Life 2016



Asia should be regarded as a Zika virus-endemic area.

Mosquitoes in Vietnam Carry Zika virus!


Date: Sun 16 Oct 2016 01:34 pm (GMT+7) Source: VN Express International [edited] <u>http://e.vnexpress.net/news/news/zika-virus-mosquitoes-detected-in-central-vietnam-3484407.html></u>

Viet Nam's National Institute of Hygiene and Epidemiology has discovered a small population of the *Aedes aegypti* mosquitoes carrying the Zika virus in the tourist town of Nha Trang in the central province of Khanh Hoa.

Out of 23,682 mosquitoes, 56 or **0.24% of the total, tested positive for Zika virus** and 26 or **0.12% for Dengue virus**, according to a study conducted by the institute from March 2015-May 2016.

Zika virus history (1947 ~ 2016)

https://www.who.int/bulletin/online_first/16-171082/en/



Why are we recognizing ZIKV as such an awful virus NOW?

Asian strains may be less pathogenic than those in Latin America.


Cite as: L. Yuan et al., Science

10.1126/science.aam7120 (2017).

A single mutation in the prM protein of Zika virus contributes to fetal microcephaly

Ling Yuan,^{1,2}* Xing-Yao Huang,³* Zhong-Yu Liu,³* Feng Zhang,^{1,2}* Xing-Liang Zhu,^{1,2}* Jiu-Yang Yu,³* Xue Ji,³ Yan-Peng Xu,³ Guanghui Li,^{1,2} Cui Li,^{1,2} Hong-Jiang Wang,³ Yong-Qiang Deng,³ Menghua Wu,⁴ Meng-Li Cheng,^{3,5} Qing Ye,³ Dong-Yang Xie,^{3,5} Xiao-Feng Li,³ Xiangxi Wang,⁶ Weifeng Shi,⁷ Baoyang Hu,⁴ Pei-Yong Shi,⁸ Zhiheng Xu,^{1,2,9}† Cheng-Feng Qin³†


Zika virus (ZIKV) has evolved into a global health threat due to its unexpected causal link to microcephaly. Phylogenetic analysis reveals that contemporary epidemic strains have accumulated multiple substitutions from their Asian ancestor. Here, we show that a single serine to asparagine substitution (S139N) in the viral polyprotein substantially increased ZIKV infectivity in both human and mouse neural progenitor cells (NPCs), led to more significant microcephaly in the mouse fetus, and higher mortality in neonatal mice. Evolutionary analysis indicates that the S139N substitution arose before the 2013 outbreak in French Polynesia and has been stably maintained during subsequent spread to the Americas. This functional adaption makes ZIKV more virulent to human NPCs, thus contributing to the increased incidence of microcephaly in recent ZIKV epidemics.



Evolutionary analysis indicates that the S139N substitution arose before the 2013 outbreak in French Polynesia and has been stably maintained during subsequent spread to the Americas.

Zika virus history (1947 ~ 2016)

https://www.who.int/bulletin/online_first/16-171082/en/



THE LANCET Infectious Diseases

Vol. 17 p. 805 August 2017

Zika virus infection and microcephaly in Vietnam

Even if <u>less</u> pathogenic, ZIKV in Asia should never be <u>non</u>-pathogenic.

Meng Ling Moi, Thi Thu Thuy Nguyen, Co Thach Nguyen, Thi Bich Hau Vu, Mya Myat Ngwe Tun, Tho Duoc Pham, Ngoc Thanh Pham, Thuan Tran, Kouichi Morita, Thi Quynh Mai Le, Duc Anh Dang, *Futoshi Hasebe

Nagasaki University, Japan; NIHE, Vietnam



Figure: Facial features of a child aged 4 months exposed to Zika virus in Vietnam

The infant was born by spontaneous vaginal delivery (bodyweight 2.6 kg; length 50 cm; head circumference 22 cm at birth).

Successful Flavivirus Vaccines

	Vaccine type	Disease
Live attenuated	By serial passaging in mouse and chicken tissue (\rightarrow YFV 17D)	Yellow fever (YF)
	SA14-14-2 strain	
	Chimeric virus containing the prM and E proteins of JEV and attenuated YFV 17D	Japanese encephalitis
Inactivated	Inactivate the attenuated SA14-14-2 strain grown in Vero cells	(JEV)
	Highly purified inactivated whole virus grown in primary chicken embryo cells	Tick-borne encephalitis


How about dengue virus (DENV) vaccines?

Challenges for Developing DENV Vaccines

- DENV consists of 4 serotypes that are substantially different from each other in the amino acid sequence of their E proteins.
- Previous infection with one serotype can predispose the severe forms of dengue (DHF/DSS) upon re-infection by another serotype.
- Endemic regions with co-circulating different serotypes have enormously expanded, followed by dramatic increase in the incidence of DHF/DSS.
- Cross-reactive non-neutralizing antibodies (such as those present after infection with a heterologous serotype in sequential infections) and neutralizing antibodies at suboptimal concentrations can lead to antibody-dependent enhancement (ADE) of FcR-bearing cells.
- ✓ Pre-existing cross-reactive T cells are also less efficient in viral clearance but can cause "cytokine storm".

"Capillary leakage" ---- Development of DHF/DSS

Dengue Vaccine Race



Ehe New York Times F.D.A. Approves the First Vaccine for Dengue Fever, but Limits Its Use

By Katie Thomas May 3, 2019

The Food and Drug Administration has approved the first vaccine for dengue, <u>Dengvaxia</u>, but placed significant restrictions on its use because the vaccine has been shown to put some people at heightened risk for a severe form of the disease.

That decision came after Sanofi announced that in rare cases, if people who never had dengue were vaccinated and later became infected, the vaccine might provoke a much more severe form of the illness.

On May 1, the F.D.A. limited its approval to people aged 9 to 16 who live in


areas where dengue is endemic and who are shown by lab testing

already to have been infected with the disease.



In Manila, relatives of children who had died after receiving the Dengvaxia vaccine attended a hearing in 2018. Philippine officials halted use of Sanofi's vaccine amid concerns about the health risks.Noel Celis/Agence France-Presse — Getty Images

Phylogenetic tree of medically important flaviviruses based on E protein amino acid diversity



Challenges for Developing Zika Virus Vaccines

- Four serotypes of DENV and Zika virus are closely related.
- Neutralizing antibody to any one of them is cross-reactive with other viruses.

Pre-existing immunity against DENV may predispose serious Zika disease (CZS), and vice versa (DHF/DSS).

V

Sci. Adv. 2019; 5 : eaav3208 27 February 2019


IMMUNOLOGY

Maternal immunity and antibodies to dengue virus promote infection and Zika virus–induced microcephaly in fetuses

Abhay P. S. Rathore^{1,2}*, Wilfried A. A. Saron¹*, Ting Lim¹, Nusrat Jahan¹, Ashley L. St. John^{1,2,3†}

Maternal DENV immunity leads to FcRn-dependent enhancement of fetal Zika virus infection.

Suboptimal immunity can be detrimental.



Challenges for Developing Zika Virus Vaccines

- Four serotypes of DENV and Zika virus are closely related.
- Neutralizing antibody to any one of them is cross-reactive with other viruses.

Pre-existing immunity against DENV may predispose serious Zika disease (CZS), and vice versa (DHF/DSS).

 A rapid emergence of ZIKV-associated Guillain-Barre syndrome (GBS) has been observed during its outbreak.

ZIKV vaccination may also induce the emergence of GBS.

Challenges for Developing Zika Virus Vaccines

- Four serotypes of DENV and Zika virus are closely related.
- Neutralizing antibody to any one of them is cross-reactive with other viruses.

Pre-existing immunity against DENV may predispose serious Zika disease (CZS), and vice versa (DHF/DSS).

• A rapid emergence of ZIKV-associated Guillain-Barre syndrome (GBS) has been observed during its outbreak.

ZIKV vaccination may induce the emergence of GBS.

Precise estimates of disease burden in Asia are limited.

Insufficient interest by policymakers in Asian countries.

KHANH HOA BIRTH COHORT STUDY

National Institute of Hygiene and Epidemiology (NIHE), Hanoi, Vietnam Khanh Hoa Provincial Public Health Service Khanh Hoa General Hospital (KHGH), Nha Trang, Vietnam

Nagasaki University, Nagasaki, Japan



Approximately 2,000 pairs of mothers and babies were enrolled.


- \checkmark Cord blood sera were tested for flavivirus serology.
- \checkmark Saliva and cord blood specimens were tested for Zika virus RNA.

Summary of Infants with Congenital Zika Virus Infection

	Sample	Age	Sample	IgM P/N ration (>2.0)			Flavi		PCR	
art 2	ID	(Y)	collecti on date	ΖΙΚν	DENV	JEV	lgG (x1000)	NT	PL	Saliva
Part	P-10	42	Jul/15	12.3	0.8	5.5	59.3	640	ND	+
	BC-54	34	Jul/27	2.0	0.7	0.6	41.7	1280	+	+
	BC-114	34	Aug/21	3.3	0.7	0.1	8.5	640	+	-
Cohort)	BC-126	38	Aug/24	3.7	0.8	0.3	29.5	640	+	-
	BC-162	29	Sep/6	3.7	2.5	2.3	72.2	1280	+	-
	BC-171	29	Sep/8	2.0	0.6	0.5	17.3	640	-	-
(Birth	BC-292	23	Oct/25	2.0	0.8	0.5	31.7	2560	-	+
Part 1 (B	BC-315	28	Nov/2	17.9	14.9	13.1	72.9	20480	-	-
	BC-321	42	Nov/6	7.9	6.0	5.8	57.4	2560	+	-
	BC-3112	21	Sep/22	8.6	2.0	0.6	10.3	1280	+	+
	BC-3786	28	Jul/18	2.0	1.4	0.5	33.4	320	ND	-
	BC-4013	25	Sep/19	2.3	0.6	1.2	24.0	640	ND	-

Incidence of congenital Zika infection: 0.54% in BC

Cases of Congenital Zika Virus Infection




Summary of Infants with Congenital Zika Virus Infection

Sample	Neutralization titer (FRNT50)						
ID	ZIKV	JEV	DENV-1	DENV-2	DENV-3	DENV-4	
P-10	640	80	160	160	160	160	
BC-54	1280	160	80	160	160	320	
BC-114	640	<80	<80	80	<80	<80	
BC-126	640	80	160	160	160	<80	
BC-162	1280	80	320	320	320	320	
BC-171	640	<80	80	160	<80	80	
BC-292	2560	80	640	640	160	320	
BC-315	20480	160	5120	5120	5120	1280	
BC-321	2560	320	160	320	<80	640	
BC-3112	1280	160	320	160	160	320	

All of them had anti-DENV antibody

→ **Pre-existing immunity against DENV predisposed CZI?**



https://www.promega.jp/resources/pubhub/inspiration/zika-perspectives-responses/

ZIKV Vaccine Candidates in Clinical Trials

Platform		Immunogen	Name	Main sponsor	Phase
DNA			VRC5283	NIAID	II
		prM-E	VRC5288	NIAID	I
			GLS-5700	GeneOne Life Science	I
mRNA		prM-E	mRNA-1325	Moderna Therapeutics	I
Inactivated virions		Whole virion	ZPIV	NIAID	I
			BBV121	Bharat Biotech	I
			PIZV	Takeda	I
			VLA1601	Valneva	I
Viral vector	Measles virus	prM-E	MV-ZIKV	Themis Bioscience	I
	Adenovirus	M-E	Ad26.ZIKV.001	Janssen	Ι
Live attenuated		Whole virion	rZIKV/D4∆30- 713	NIAID	I

TORCH complex

Toxoplasma

Herpes simplex virus


Others

(Syphilis, Zika virus)

Rubella


The only TORCH pathogen that we have useful vaccines against all over the world

Cytomegalovirus



Rubella cases by gender, age and vaccination status (2013)






once at private clinic during childhood.

at private clinic at junior high school ages.

Rubella-containing vaccine had not been introduced into national immunization program until 2015 in Vietnam.

Countries Using Rubella Vaccine in National Immunization Schedule, 2012





Seroprevalence of rubella in the cord blood of pregnant women and congenital rubella incidence in Nha Trang, Vietnam

Masami Miyakawa^{a,1}, Hiroshi Yoshino^b, Lay Myint Yoshida^b, Emilia Vynnycky^{c,f}, Hideki Motomura^a, Le Huu Tho^d, Vu Dinh Thiem^e, Koya Ariyoshi^b, Dang Duc Anh^e, Hiroyuki Moriuchi^{a,*}

100


75

% seronegative

Rubella-IgM positive in 3 infants

⇒ CRI rate 151 (95%CI: 0-322) per 100,000 live births

- Their mothers lived in different residential areas.
- No outbreak was reported in the area during study period.




Mathematical modeling estimated that 3788 (95%CI: 3283-4143) infants with CRS would be born annually in Vietnam with 234 (95%CI: 207-262) cases per 100,000 live births



- > A total of 38 babies were enrolled (2.1 cases per 1000 live births).
- ≻ M : F = 17 (45%) : 21 (55%)
- ➤ 14 (37%) died.





Viet Nam Launches Largest Measles-Rubella Immunization Campaign with United Nations Support

Ha Noi, 11 October 2014 -

The current campaign aims to reach 23 million children ages 1-14 with the MR vaccine over the next six months.

Earlier this year, Viet Nam witnessed an unprecedented rise in measles infections which affected more than 5000 children including the loss of more than 140 young lives.

The MR immunization campaign, which lasts through to February 2015, is part of Viet Nam's commitment to the Measles & Rubella Initiative, a global partnership to ensure that no child dies from measles or is born with congenital rubella syndrome. The Measles & Rubella Initiative is led by the American Red Cross, the United Nations Foundation, the U.S. Centers for Disease Control and Prevention, UNICEF and the World Health Organization.


→ followed by the routine immunization for children aged 18 months



UNICEF Viet Nam\2014\Truong Viet Hung



Rubella in Vietnam



Routine immunization for children aged 18 months

*Vaccine 2014; 32: 7065 **WHO WPRO

Pregnant women

2009-2010 Birth Cohort


Rubella	Tested, N	Positive, N (%)
RT-PCR (saliva)	-	-
IgM	1,988	3 (0.15%)
lgG	1,988	1414 (71.1%)

2017-2018 Birth Cohort

Rubella	Tested, N	Positive, N (%)
RT-PCR (saliva)	2,038	0 (0%)
IgM	2,038	0 (0%)
lgG	1,977	1,564 (79.1%)

More than 20% of pregnant women are still susceptible to rubella.

Seroprevalence of Rubella among Pregnant Women in Nha Trang, Vietnam (2017-2018)



Vaccine is a Diamond



Not only Development but also Distribution of Vaccines to those who need is critical.